Analysts have been eager to weigh in on the Healthcare sector with new ratings on Omeros (OMER – Research Report) and SAGE Therapeutics (SAGE – Research Report).
Omeros (OMER)
In a report released yesterday, Greg Harrison from Bank of America Securities reiterated a Sell rating on Omeros, with a price target of $4.00. The company’s shares closed last Monday at $4.98.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Omeros with a $6.33 average price target.
See the top stocks recommended by analysts >>
SAGE Therapeutics (SAGE)
Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on SAGE Therapeutics yesterday and set a price target of $55.00. The company’s shares closed last Monday at $45.72.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAGE Therapeutics with a $48.33 average price target, implying a 9.1% upside from current levels. In a report issued on January 25, Needham also maintained a Buy rating on the stock with a $70.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OMER:
